Evidence-Based Medicine Guidelines
Cyclin-dependent kinase inhibitor for advanced breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Cyclin-dependent Kinase Inhibitor for Advanced Breast Cancer." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305408/all/_________Cyclin_dependent_kinase_inhibitor_for_advanced_breast_cancer______.
Cyclin-dependent kinase inhibitor for advanced breast cancer. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305408/all/_________Cyclin_dependent_kinase_inhibitor_for_advanced_breast_cancer______. Accessed September 16, 2024.
Cyclin-dependent kinase inhibitor for advanced breast cancer. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305408/all/_________Cyclin_dependent_kinase_inhibitor_for_advanced_breast_cancer______
Cyclin-dependent Kinase Inhibitor for Advanced Breast Cancer [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 September 16]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305408/all/_________Cyclin_dependent_kinase_inhibitor_for_advanced_breast_cancer______.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cyclin-dependent kinase inhibitor for advanced breast cancer
ID - 1305408
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305408/all/_________Cyclin_dependent_kinase_inhibitor_for_advanced_breast_cancer______
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
